SMART-TRIAL is Looking for the Future Stars of MedTech
SMART-TRIAL announces the Future Stars of MedTech program to help early stage MedTech companies with clinical data collection and regulatory compliance. The program will equip participating companies with clinical data collection tools, professional services, networking and discount schemes to facilitate their clinical and regulatory pathway. The aim of the program is to level the playing field by giving the early stage innovators access to the same resources as their more established peers.
With heightened requirements on post-market activities and clinical data under the EU Medical Device Regulation (MDR), the MedTech industry is faced with the difficult challenge of collecting more clinical data. This is bound to impact regulatory complexity and the cost of clinical operations and market access.
“The process of bringing new medical devices to market is proving more prohibitive than ever before. Clinical evaluation is one of the biggest regulatory challenges early stage MedTech companies face, and having quality clinical evidence is crucial for both market access and funding. We are launching the
Future Stars of MedTech program to help these companies removing the dilemma of having to choose between their budgets and high-quality clinical data.” says Pall Johannesson CEO
Facilitating Collection of Clinical Evidence
The Future Stars of MedTech Program offers a wide range of resources to participants. Included are discount schemes on all SMART-TRIAL services during first clinical stages. Templates to ease regulatory compliance, and access to SMART-TRIAL’s MedTech expert and CRO network. The program will create a community of companies to share experiences while growing together.
Johannesson points out that with the EU heightening its regulations, access to new and existing medical technology is proving more difficult. More clinical evidence is now required to be collected and managed by MedTech companies to keep products on market.“With the right resources, early stage companies will be more likely to succeed in today’s market because they will have the data that can prove device efficacy, safety, and usability. This will also prove invaluable in further product development, funding, market access, and marketing” adds Johannesson.
For more information and eligibility criteria please visit: https://info.smart-trial.co/program/future-stars-of-medtech
Jón I. Bergsteinsson
VP of Global Business Development
Tel: +45 42 70 70 03
Email: jib@smart-trial.co
